Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Advertisement

Advertisement




May
15
Today In Oncology
Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers
Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC
Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL
FDA Approves Combination Regimen for Newly Diagnosed AML
Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo